<DOC>
	<DOC>NCT02164006</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.</brief_summary>
	<brief_title>Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Confirmed diagnosis of Hodgkin's Lymphoma Relapsed or refractory after an autologous stem cell transplant (ASCT) or at least two prior multiagent chemotherapy regimens in patients not candidates for ASCT Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 Any major surgery, chemotherapy or immunotherapy within the last 21 days Known hepatitis B virus, hepatitis C virus or HIV infection Autologous hematologic stem cell transplant within 3 months of study entry. Patients who had prior Allogeneic hematologic stem cell transplant are excluded</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hodgkin's</keyword>
</DOC>